![]() |
|||||||||||||
|
Nabumetone |
|
Nabumetone
|
|
| Systematic (IUPAC) name | |
| 4-(6-methoxy-2-naphthyl)-2-butanone | |
| Identifiers | |
| CAS number | |
| ATC code | M01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C15H16O2 |
| Mol. mass | 228.29 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | > 99% (active metabolite) |
| Metabolism | Hepatic, to active metabolite 6-methoxy-2-naphthylacetic acid |
| Half life | 23 hours (active metabolite) |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
POM |
| Routes | Oral |
Nabumetone is a non-steroidal anti-inflammatory drug1 of the arylalkanoic acid family (which includes diclofenac). It is available under numerous brand names, such as Relafen, Relifex and Gambaran.
It is used to treat pain or inflammation caused by arthritis. Nabumetone works by reducing the effects of hormones that cause pain and inflammation.
It has been shown to have a slightly lower risk of gastrointestinal side effects than most other non-selective NSAID's.
|
|||||||||||||||||||||||